查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2014496

马用药品和补充剂市场：按产品类型、治疗领域、给药途径、剂型、动物年龄层、最终用户和分销管道划分 - 全球市场预测（2026-2032 年）

Equine Pharmaceuticals & Supplements Market by Product Type, Therapeutic Category, Route Of Administration, Formulation, Animal Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年，马用药品和补充剂市场价值10.3亿美元，预计到2026年将成长至10.8亿美元，复合年增长率为6.08%，到2032年将达到15.6亿美元。

主要市场统计数据
基准年（2025 年） 10.3亿美元
预计年份（2026年） 10.8亿美元
预测年份（2032年） 15.6亿美元
复合年增长率 (%) 6.08%

对马匹治疗市场进行概述，重点介绍临床环境中的临床重点、监管责任和相关人员的期望。

马用药品和营养补充剂领域需要采取重点突出的方法，以平衡临床需求、监管要求和商业性可行性。日益复杂的治疗方法、多样化的终端使用者以及多种多样的剂型，使得准确性、安全性和供应可靠性至关重要。兽医和农场管理者需要能够为成年马、幼驹和一岁马带来可预测疗效的产品，而研究机构和医院则优先考虑循证配方和完善的不利事件监测。

技术创新、监管现代化和不断发展的兽医模式如何从根本上改变马匹治疗药物的产品开发和交付。

马匹治疗领域正受到多种相互关联的因素的影响而重塑，这些因素正在改变产品的研发、检验和交付方式。生技药品和疫苗平台的进步使得更有针对性的预防方法成为可能，而对合理使用抗生素的需求则促使製剂研发人员和处方医生转向更精细的抗感染策略和替代性辅助疗法。同时，数位健康工具和远端医疗正在改变兽医咨询的频率，并实现远端监测，这正在影响产品的处方方式和用药依从性的追踪方式。

评估美国于 2025 年对马用治疗药物价值链实施的关税措施在营运、临床和策略方面的多方面影响。

美国2025年实施的关税措施对马用药品和补充剂相关企业的营运和策略决策产生了重大而多方面的影响。进口原料药和成品的成本结构受到直接影响，迫使采购团队加快重新评估供应商组合併选择替代来源。实际上，为了降低未来的政策风险，本地采购、库存缓衝以及在某些情况下将关键生产流程迁回或近岸外包变得更加重要。

可操作的细分资讯揭示了产品类型、治疗分类、分销管道、给药途径、最终用户、配方和年龄组如何影响临床应用。

在马匹治疗领域，细分是实现实际差异化的最直接方法。综合考虑产品类型、治疗分类、分销管道、给药途径、最终用户、製剂和动物年龄组等因素，可以发现几种不同的模式。药品和补充剂是互补的类别；药品主要用于急性期和疾病特异性干预，而补充剂则广泛用于预防和长期护理计划中的结缔组织支持。在治疗类别中，感染疾病和抗发炎药物仍然是临床实践的核心。在抗感染药方面，当需要经验性治疗时，应重点使用Aminoglycosides、大环内酯类、青霉素类、磺胺类药物和四环霉素；而在感染疾病方面，则需要在皮质类固醇策略和非类固醇消炎剂（NSAID）治疗之间取得平衡，以控制疼痛和炎症，同时最大限度地降低全身风险。

区域洞察分析美洲、欧洲、中东、非洲和亚太地区马匹护理市场的需求推动要素、监管差异和商业化策略。

区域趋势影响需求驱动因素、监管预期和商业化策略，但这些影响往往被全球产品团队低估。在美洲，由于临床基础设施相对完善，且集中于大规模兽医院和专业马科诊所，实证医学药物和高端补充剂的推广应用十分活跃。该地区的临床方案和支付模式有利于对新型疫苗和生物製药的投资，而成熟的分销网络则支持直接向兽医院和线上药房管道销售产品。

从企业观点强调与竞争对手合作、注重创新、製造策略和伙伴关係模式，这塑造了我们在马匹治疗领域的领导地位。

马用药市场的竞争格局呈现出多元化的特点，既有大型动物用药品公司，也有专业兽药公司、生技创新企业和药局。老字型大小企业通常利用其庞大的製造地、丰富的产品系列和全球分销协议，以支持其产品广泛渗透到临床实践中。虽然这些公司倾向于优先发展实证医学产品，例如疫苗、循环系统药物和主要感染疾病物，但它们也会投资于产品生命週期管理和配方改进，以保持其在临床上的市场地位。

为领导者提供切实可行的、高优先级的建议，以加强马匹治疗领域的供应链韧性、扩大临床证据并优化商业化。

产业领导者应推动一系列合作倡议，以增强韧性、加速临床应用并改善商业性成果。首先，他们应实现供应商网路多元化，并加快原料药(API) 和成品替代来源的认证，以降低政策衝击和关税造成的成本波动风险。同时，他们应优先投资于製剂科学，以简化给药流程、提高药物在各种物流条件下的稳定性，并增强特定年龄组的耐受性，从而提高农场和移动诊所等场所使用者的实际用药依从性。

研究结果得到了透明的混合方法研究途径结合了相关人员访谈、文献综述、细分框架和检验方案。

本文提出的见解源自于一项混合方法研究，旨在平衡关键相关人员的见解与严谨的二手证据。主要资料收集包括对执业兽医、医院管理人员、马场采购经理、製剂科学家和高级销售主管的结构化访谈，从而获得关于临床决策者和营运限制的实地观点。此外，还透过查阅同行评审的临床文献、监管指南、专利申请和公开的临床试验註册信息，补充了这些定性信息，以确保技术准确性并为新兴创新提供背景信息。

摘要概述了整个马匹治疗生态系统中相关人员的策略重点、新兴风险和机会途径。

最后，马用药品和营养补充剂行业的相关人员必须平衡两大挑战：既要提供临床疗效可靠且易于使用的治疗方法，又要应对日益复杂的政策和供应链环境。在治疗重点、不断变化的经销管道和区域监管差异的相互作用下，灵活的筹资策略、清晰的临床证据和适应性强的经营模式至关重要。 2025年的关税趋势凸显了供应链多元化和积极遵守贸易法规的必要性，这将推动策略转型，并在不久的将来影响采购和生产决策。

目录

第一章 引言

第二章 分析方法

  • 分析设计
  • 分析框架
  • 市场规模预测
  • 数据三角测量
  • 分析结果
  • 分析的前提条件
  • 分析的局限性

第三章执行摘要

  • 首席体验长的观点
  • 市场规模和成长趋势
  • 市占率分析（2025 年）
  • FPNV定位矩阵（2025）
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入（GTM）策略

第五章 市场洞察

  • 消费者分析与最终用户观点
  • 消费者体验基准测试
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第六章：美国关税的累积影响（2025 年）

第七章：人工智慧（AI）的累积影响（2025 年）

第八章：马用药品和补充品市场：依产品类型划分

  • 製药
  • 补充

第九章：马用药品和补充品市场：依治疗领域划分

  • 麻醉剂
  • 抗感染药物
    • Aminoglycosides
    • 大环内酯类
    • 青霉素
    • 磺胺类药物药物
    • 四环霉素
  • 抗发炎药
    • 皮质类固醇
    • NSAID
  • 循环系统药物
  • 消化器官系统药物
  • 荷尔蒙製剂
  • 神经系统药物
  • 疫苗

第十章：马用药品和补充品市场：依给药途径划分

  • 注射药物
    • 肌肉内部
    • 静脉
    • 皮下
  • 口服
    • 粉末
    • 糖浆
    • 药片
  • 外用

第十一章：马用药品和补充品市场：按剂型划分

  • 奶油
  • 乳液
  • 凝胶
  • 粉末
  • 解决方案
  • 药片

第十二章：马匹药品和营养补充品市场：依动物年龄层划分

  • 成年马
  • 驹
  • 一岁马（幼驹）

第十三章：马用药品和补充品市场：依最终用户划分

  • 马场
  • 研究机构和学术机构
  • 兽医诊所和上门服务
  • 动物医院

第十四章：马用药品和补充品市场：依通路划分

  • 网路药房
  • 零售药房
  • 兽医医院和诊所
  • 兽药

第十五章：马用药品和补充品市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：马用药品和补充品市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章：马用药品和补充品市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国马用药品和补充品市场

第十九章：中国马用药品和补充品市场

第20章 竞争格局

  • 市场集中度分析（2025 年）
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析（2025 年）
  • 产品系列分析（2025 年）
  • 基准分析（2025 年）
  • AddoVet Ltd.
  • Affinity Petcare SA
  • Alltech Inc.
  • Audevard SAS
  • Bayer Animal Health GmbH
  • Bimeda Inc.
  • Boehringer Ingelheim GmbH & Co. KG
  • CEVA Sante Animale SAS
  • Chanelle Pharma Group Ltd.
  • Dechra Veterinary Products plc
  • Elanco Animal Health Incorporated
  • Hallmarq Veterinary Imaging Ltd.
  • Intas Animal Health Ltd.
  • Kentucky Equine Research LLC
  • Kyoritsu Seiyaku Corporation
  • Lloyd Inc.
  • Merck & Co., Inc.
  • Norbrook Laboratories Ltd.
  • Ouro Fino Saude Animal SA
  • Protexin Healthcare Ltd.
  • Sound Technologies Inc.
  • Vetoquinol SA
  • Virbac SA
  • WF Young Inc.
  • Zoetis Inc.
Product Code: MRR-4348D129FACA

The Equine Pharmaceuticals & Supplements Market was valued at USD 1.03 billion in 2025 and is projected to grow to USD 1.08 billion in 2026, with a CAGR of 6.08%, reaching USD 1.56 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.03 billion
Estimated Year [2026] USD 1.08 billion
Forecast Year [2032] USD 1.56 billion
CAGR (%) 6.08%

A concise orientation to the equine therapeutics landscape highlighting clinical priorities, regulatory responsibilities, and stakeholder expectations across care settings

The equine pharmaceuticals and supplements domain demands a focused orientation that balances clinical need, regulatory oversight, and commercial practicality. Increasingly complex therapeutic regimens, diversified end users, and a broader array of delivery formats have combined to create a landscape where precision, safety, and supply reliability are paramount. Veterinarians and farm managers require products that deliver predictable outcomes across adult horses, foals, and yearlings, while research institutions and hospitals prioritize evidence-backed formulations and robust adverse event monitoring.

Across product distinctions, pharmaceuticals continue to anchor acute care and disease-specific treatments, while supplements are often deployed for preventive care, performance support, and long-term musculoskeletal health. Meanwhile, distribution has broadened beyond traditional veterinary pharmacies to include online pharmacies and integrated hospital channels, introducing new considerations around cold-chain management, authentication, and regulatory compliance. Transitioning from concept to clinic also involves navigating evolving therapeutic categories such as anti-infectives and anti-inflammatories, where formulation and route of administration materially impact clinical adoption.

Taken together, these dynamics require strategic alignment across R&D, manufacturing, regulatory affairs, and commercial teams. By foregrounding clinical utility, safety, and distribution integrity, stakeholders can better prioritize investments and interventions that deliver measurable value in equine care settings.

How technological innovation, regulatory modernization, and evolving veterinary care models are fundamentally altering product development and delivery in equine therapeutics

The equine therapeutics landscape is being reshaped by multiple intersecting forces that are altering how products are developed, validated, and delivered. Advances in biologics and vaccine platforms are enabling more targeted preventive approaches, even as antimicrobial stewardship imperatives push formulators and prescribers toward refined anti-infective strategies and alternative supportive modalities. Concurrently, digital health tools and telemedicine are changing the cadence of veterinary consultations and enabling remote monitoring, which affects how products are prescribed and how adherence is tracked.

Supply chain and manufacturing practices are also evolving. Contract manufacturing and regional production hubs are gaining traction as companies seek to shorten lead times and reduce reliance on single-source active pharmaceutical ingredient suppliers. At the same time, e-commerce and direct-to-practice distribution channels are forcing companies to rethink packaging, serialization, and cold-chain protocols to maintain product integrity and regulatory traceability. These shifts are complemented by a heightened focus on formulation science, where innovations in topical gels, oral powders, and injectable presentations are improving bioavailability and user convenience.

Together, these transformations create opportunities for differentiated value propositions, but they also impose new requirements for cross-functional coordination. Firms that align clinical evidence generation with flexible manufacturing, digital-enabled distribution, and clear regulatory strategies will be better positioned to translate innovation into commercial and clinical impact.

Assessing the multifaceted operational, clinical, and strategic consequences of the United States tariff measures introduced in 2025 on the equine therapeutics value chain

The 2025 tariff measures introduced by the United States have had a material and multifaceted influence on the operational and strategic calculus of organizations involved in equine pharmaceuticals and supplements. Cost structures for imported active ingredients and finished goods were directly affected, prompting procurement teams to reassess supplier portfolios and to accelerate qualification of alternative sources. In practice, this has meant a stronger emphasis on regional sourcing, inventory buffering, and in some cases, reshoring or nearshoring of critical manufacturing steps to mitigate future policy risk.

Beyond procurement, distribution patterns shifted as companies rebalanced logistics to minimize tariff exposure. This rebalancing increased demand for contract manufacturers and third-party logistics providers with cross-border capabilities, and it elevated the importance of tariff classification, origin documentation, and trade compliance expertise within commercial operations. Smaller manufacturers and specialized compounding pharmacies felt disproportionate pressure, as they typically have less flexibility to absorb cost shocks or negotiate bulk purchase discounts.

Clinically, the tariff environment translated into tighter price negotiations with veterinary customers and a renewed focus on demonstrating cost-effectiveness and therapeutic differentiation. As a result, product teams prioritized investments that enhanced formulation efficiency, extended shelf life, or enabled lower-cost routes of administration. From a strategic perspective, the tariffs catalyzed a broader industry reassessment of supply chain resilience, corporate tax planning, and the merits of localized manufacturing footprints versus a globally optimized but policy-exposed supply chain.

Actionable segmentation intelligence revealing how product types, therapeutic classes, distribution channels, administration routes, end users, formulations, and age groups inform clinical adoption

Segmentation offers the most direct route to actionable differentiation in equine therapeutics, and several clear patterns emerge when product type, therapeutic class, distribution, route of administration, end user, formulation, and animal age group are considered together. Pharmaceuticals and supplements function as complementary categories; pharmaceuticals are prioritized for acute and disease-specific interventions, while supplements are more commonly adopted for preventive and connective tissue support across long-term care plans. Within therapeutic categories, anti-infectives and anti-inflammatories remain core pillars of clinical practice, with anti-infectives emphasizing agents such as aminoglycosides, macrolides, penicillins, sulfonamides, and tetracyclines when empirical coverage is needed, and anti-inflammatories balancing corticosteroid strategies against NSAID regimens to manage pain and inflammation while minimizing systemic risk.

Distribution preferences are shifting as veterinarians and hospitals increasingly source through online pharmacies and integrated veterinary hospital channels, reducing friction for repeat prescriptions and enabling better adherence tracking. Injectable presentations continue to be essential for many acute and inpatient interventions, with intramuscular, intravenous, and subcutaneous options selected based on onset requirements and tolerability. Oral forms, particularly powders, syrups, and tablets, are favored for outpatient management and for foals where palatability and dosing precision are critical. Topical formulations, including creams, emulsions, and gels, offer targeted local therapy that reduces systemic exposure and supports recovery in musculoskeletal and dermatological conditions.

End-user segmentation reveals that equine farms and veterinary hospitals are primary purchasers of high-value therapeutic products, whereas research institutions and ambulatory services increasingly influence early adoption of novel biologics and vaccines. Formulation choices must therefore reconcile handling preferences of field practitioners with the stability demands of hospital pharmacies. Moreover, age-group considerations are integral to product positioning: adult horses often require chronic management solutions focused on musculoskeletal health and cardiovascular support, foals demand gentler oral and injectables with careful dosing, and yearlings fall into a transitional category where both preventive supplements and standard pharmaceuticals are commonly used. By integrating these segmentation dimensions, product teams can better align development priorities with user workflows and clinical decision-making criteria.

Regional intelligence unpacking demand drivers, regulatory variation, and commercialization strategies across the Americas, EMEA, and Asia-Pacific equine care markets

Regional dynamics shape demand drivers, regulatory expectations, and commercialization strategies in ways that are often underappreciated by global product teams. In the Americas, clinical infrastructures are relatively advanced and concentrated in high-volume veterinary hospitals and specialist equine clinics, yielding strong uptake of evidence-backed pharmaceuticals and premium supplements. Clinical protocols and payer models in this region encourage investment in novel vaccines and biologics, and the presence of well-established distribution networks supports both direct-to-practice and online pharmacy channels.

In Europe, Middle East and Africa, regulatory heterogeneity and differing farm structures create a mosaic of commercial approaches. European markets emphasize stringent pharmacovigilance and antimicrobial stewardship, which affects labeling, usage guidance, and the acceptability of certain systemic agents. Middle Eastern and African subregions introduce additional complexity with variations in import logistics, cold-chain infrastructure, and localized disease pressure, all of which influence product prioritization and go-to-market tactics.

Asia-Pacific presents a distinct mix of rapid adoption in urban veterinary centers and growing demand from emerging equine leisure and sport segments. Manufacturing capacity and ingredient sourcing in the region can be advantageous for supply continuity, yet regulatory frameworks and import practices vary considerably from market to market. Across all regions, trade policies and tariff dynamics continue to exert influence on sourcing decisions, and companies that craft region-specific regulatory filings, distribution partnerships, and pricing strategies will be better positioned to capture the full spectrum of demand.

Competitive and collaborative company-level perspectives emphasizing innovation focus, manufacturing strategy, and partnership models shaping equine therapeutics leadership

Competitive landscapes in equine therapeutics are characterized by a mixture of large animal health companies, specialized veterinary pharmaceutical firms, biotech innovators, and compounding pharmacies. Established firms often leverage broad manufacturing footprints, diversified portfolios, and global distribution agreements to support widespread clinical penetration. They tend to prioritize high-evidence products such as vaccines, cardiovascular agents, and key anti-infectives, while also investing in lifecycle management and formulation improvements to retain clinical preference.

Specialist players and biotech entrants are differentiating through targeted innovation, such as next-generation biologics, improved analgesic modalities, and formulation science that enhances bioavailability or reduces administration frequency. These firms frequently pursue strategic partnerships with research institutions and veterinary hospitals to accelerate clinical validation and to access early-adopter cohorts. Contract manufacturing organizations and third-party logistics providers are increasingly central to competitive positioning, enabling faster market entry and flexible scaling while allowing companies to control capital expenditure.

Across the competitive set, successful strategies include clear articulation of clinical value, robust regulatory dossiers, and integrated commercial models that combine direct engagement with veterinarians, digital education platforms, and efficient distribution. Firms that can demonstrate reproducible clinical outcomes, secure supply chain resilience, and offer effective support services for end users will generally achieve stronger market traction and more durable customer relationships.

Practical and prioritized recommendations for leaders to reinforce supply resilience, amplify clinical evidence, and optimize commercialization in equine therapies

Industry leaders should pursue a coordinated set of actions that enhance resilience, accelerate clinical adoption, and improve commercial outcomes. First, diversify supplier networks and accelerate qualification of alternative API and finished-goods sources to reduce exposure to policy shocks and tariff-driven cost volatility. Concurrently, prioritize investments in formulation science that lower administration complexity, improve stability under varied logistics conditions, and address specific age-group tolerability, thereby increasing real-world adherence among farm-based and ambulatory users.

Second, deepen engagement with veterinary stakeholders through targeted clinical evidence generation and practitioner-focused education programs. Generating pragmatic clinical data that highlights cost-effectiveness, safety, and ease of administration will support uptake among hospitals, clinics, and farm managers. Third, optimize distribution by combining direct-to-practice models with validated online pharmacy channels, ensuring serialization and traceability to preserve product integrity and combat counterfeiting.

Fourth, prepare regulatory and trade-compliance strategies that anticipate tariff shifts and heterogeneous regional requirements. Building capabilities in tariff classification, origin documentation, and regulatory harmonization will accelerate market access and reduce time-to-shelf. Finally, explore collaborative ventures with contract manufacturers, research institutions, and technology providers to share risk, accelerate innovation, and create bundled service offerings that enhance practitioner value propositions. These coordinated measures will support sustainable growth while managing near-term operational exposure.

Transparent mixed-methods research approach combining stakeholder interviews, literature review, segmentation frameworks, and validation protocols to underpin findings

The findings presented here are derived from a mixed-methods research approach designed to balance primary stakeholder insight with rigorous secondary evidence. Primary data collection included structured interviews with practicing veterinarians, hospital administrators, procurement leads at equine farms, formulation scientists, and senior commercial executives, providing frontline perspectives on clinical decision drivers and operational constraints. These qualitative inputs were complemented by a review of peer-reviewed clinical literature, regulatory guidance, patent filings, and publicly available clinical trial registries to ensure technical accuracy and to contextualize emergent innovations.

Analytical frameworks employed include segmentation analysis across product type, therapeutic category, distribution channel, route of administration, end user, formulation, and age group, as well as scenario planning to evaluate policy and supply chain contingencies. Triangulation was used at multiple stages to validate insights, combining interview evidence with secondary documentation and cross-regional trade data. An expert panel review provided an additional layer of validation, focusing on clinical plausibility and commercial relevance. Limitations include regional variation in data availability and the evolving nature of policy interventions that may change the competitive environment; where appropriate, assumptions and confidence levels are documented in the methodology annex to aid interpretation.

Concluding synthesis crystallizing strategic priorities, emergent risks, and opportunity pathways for stakeholders across the equine therapeutics ecosystem

In closing, stakeholders operating in the equine pharmaceuticals and supplements sector must reconcile a dual imperative: deliver clinically robust, user-friendly therapies while managing an increasingly complex policy and supply chain environment. The interplay of therapeutic priorities, distribution channel evolution, and regional regulatory variation requires nimble sourcing strategies, clear clinical evidence, and adaptive commercial models. Tariff dynamics introduced in 2025 have underscored the necessity of supply chain diversification and proactive trade compliance, catalyzing strategic shifts that will influence sourcing and manufacturing decisions for the foreseeable future.

Equally important is the need to align product development with real-world veterinary workflows and age-specific dosing considerations, ensuring that formulations meet the practical demands of equine farms, ambulatory services, research institutions, and hospitals. Organizations that integrate rigorous clinical validation with flexible manufacturing arrangements and targeted regional strategies will be best placed to capture sustained value. Ultimately, the most successful participants will be those that translate technical innovation into clear practitioner benefits while maintaining operational resilience against external shocks.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Equine Pharmaceuticals & Supplements Market, by Product Type

  • 8.1. Pharmaceuticals
  • 8.2. Supplements

9. Equine Pharmaceuticals & Supplements Market, by Therapeutic Category

  • 9.1. Anesthetic Agents
  • 9.2. Anti-Infectives
    • 9.2.1. Aminoglycosides
    • 9.2.2. Macrolides
    • 9.2.3. Penicillins
    • 9.2.4. Sulfonamides
    • 9.2.5. Tetracyclines
  • 9.3. Anti-Inflammatories
    • 9.3.1. Corticosteroids
    • 9.3.2. NSAIDs
  • 9.4. Cardiovascular Agents
  • 9.5. Gastrointestinal Agents
  • 9.6. Hormonal Preparations
  • 9.7. Nervous System Agents
  • 9.8. Vaccines

10. Equine Pharmaceuticals & Supplements Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Intramuscular
    • 10.1.2. Intravenous
    • 10.1.3. Subcutaneous
  • 10.2. Oral
    • 10.2.1. Powders
    • 10.2.2. Syrups
    • 10.2.3. Tablets
  • 10.3. Topical

11. Equine Pharmaceuticals & Supplements Market, by Formulation

  • 11.1. Creams
  • 11.2. Emulsions
  • 11.3. Gels
  • 11.4. Powders
  • 11.5. Solutions
  • 11.6. Tablets

12. Equine Pharmaceuticals & Supplements Market, by Animal Age Group

  • 12.1. Adult Horses
  • 12.2. Foals
  • 12.3. Yearlings

13. Equine Pharmaceuticals & Supplements Market, by End User

  • 13.1. Equine Farms
  • 13.2. Research Institutions & Academics
  • 13.3. Veterinary Clinics & Ambulatory Services
  • 13.4. Veterinary Hospitals

14. Equine Pharmaceuticals & Supplements Market, by Distribution Channel

  • 14.1. Online Pharmacies
  • 14.2. Retail Pharmacies
  • 14.3. Veterinary Hospitals & Clinics
  • 14.4. Veterinary Pharmacies

15. Equine Pharmaceuticals & Supplements Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Equine Pharmaceuticals & Supplements Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Equine Pharmaceuticals & Supplements Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Equine Pharmaceuticals & Supplements Market

19. China Equine Pharmaceuticals & Supplements Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. AddoVet Ltd.
  • 20.6. Affinity Petcare SA
  • 20.7. Alltech Inc.
  • 20.8. Audevard SAS
  • 20.9. Bayer Animal Health GmbH
  • 20.10. Bimeda Inc.
  • 20.11. Boehringer Ingelheim GmbH & Co. KG
  • 20.12. CEVA Sante Animale SAS
  • 20.13. Chanelle Pharma Group Ltd.
  • 20.14. Dechra Veterinary Products plc
  • 20.15. Elanco Animal Health Incorporated
  • 20.16. Hallmarq Veterinary Imaging Ltd.
  • 20.17. Intas Animal Health Ltd.
  • 20.18. Kentucky Equine Research LLC
  • 20.19. Kyoritsu Seiyaku Corporation
  • 20.20. Lloyd Inc.
  • 20.21. Merck & Co., Inc.
  • 20.22. Norbrook Laboratories Ltd.
  • 20.23. Ouro Fino Saude Animal S.A.
  • 20.24. Protexin Healthcare Ltd.
  • 20.25. Sound Technologies Inc.
  • 20.26. Vetoquinol SA
  • 20.27. Virbac SA
  • 20.28. W.F. Young Inc.
  • 20.29. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANESTHETIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANESTHETIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANESTHETIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CARDIOVASCULAR AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CARDIOVASCULAR AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CARDIOVASCULAR AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GASTROINTESTINAL AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GASTROINTESTINAL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GASTROINTESTINAL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY HORMONAL PREPARATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY HORMONAL PREPARATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY HORMONAL PREPARATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NERVOUS SYSTEM AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NERVOUS SYSTEM AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NERVOUS SYSTEM AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SYRUPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SYRUPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SYRUPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EMULSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EMULSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EMULSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ADULT HORSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ADULT HORSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ADULT HORSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FOALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FOALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FOALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY YEARLINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY YEARLINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY YEARLINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EQUINE FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EQUINE FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EQUINE FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY CLINICS & AMBULATORY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY CLINICS & AMBULATORY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY CLINICS & AMBULATORY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 255. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 256. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 257. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 258. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 259. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 260. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 261. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 262. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY